1
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Idec Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, April 7, 1998: US05736137 (387 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


2
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Burns Doane Swecker & Mathis, July 7, 1998: US05776456 (187 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


3
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Burns Doane Swecker & Mathis, December 1, 1998: US05843439 (100 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


4
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. IDEC Pharmaceuticals Corporation, Robin L Teskin, Pillsbury Winthrop, January 27, 2004: US06682734 (35 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


5
Anderson Darrell R, Rastetter William H, Hanna Nabil, Leonard John E, Newman Roland A, Reff Mitchell E: Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma.. Idec Pharma, September 6, 1995: EP0669836-A1 (32 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


6
Anderson Darrell R, Hanna Nabil, Leonard John E, Newman Roland A, Reff Mitchell E, Rastetter William H: Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma. Idec Pharma, January 8, 1997: EP0752248-A1 (20 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


7
Anderson Darrell R, Rastetter William H, Hanna Nabil, Leonard John E, Newman Roland A, Reff Mitchell E: Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma. Idec Pharmaceuticals Corporation, sWEISS Steven M, May 26, 1994: WO/1994/011026 (4 worldwide citation)

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


8

9
Darrell R Anderson, Nabil Hanna, John E Leonard: Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma. Idec Pharmaceuticals Corporation, JIANG JIANCHENG, November 16, 1994: CN93121424

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...


10
Darrell R Anderson, Nabil Hanna, John E Leonard, Roland A Newman, Mitchell E Reff, William H Rastetter: Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Idec Pharmaceuticals Corporation, Pillsbury Winthrop, August 7, 2003: US20030147885-A1

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, an ...